Physician profile
Mitchell Burnbaum
NPI 1700866159
$3,557.50
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $430 · 2021: $878 · 2022: $674 · 2023: $476 · 2024: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $381.95 | 2019-2024 | Vumerity, Tysabri, Skyclarys |
| Novartis Pharmaceuticals Corporation | $355.91 | 2019-2023 | |
| Emd Serono, INC. | $351.59 | 2019-2024 | Mavenclad |
| Ucb, INC. | $278.01 | 2019-2024 | Rystiggo, Fintepla |
| Abbvie INC. | $244.18 | 2021-2024 | Ubrelvy, Qulipta |
| Genentech USA, INC. | $238.30 | 2019-2024 | Ocrevus, Enspryng |
| Lilly USA, LLC | $205.74 | 2019-2024 | Amyvid, Emgality, Reyvow |
| Genzyme Corporation | $180.57 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $158.12 | 2019-2022 | |
| Celgene Corporation | $120.30 | 2019-2024 | Zeposia |
| Ani Pharmaceuticals, INC. | $119.92 | 2024 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $98.56 | 2019-2022 | |
| Tanabe Pharma America, INC. | $69.02 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $67.39 | 2020-2021 | |
| Pfizer INC. | $61.70 | 2021-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $49.05 | 2021-2022 | |
| Lundbeck LLC | $46.59 | 2019-2023 | Vyepti |
| Neurelis, INC. | $46.53 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $43.62 | 2022 | |
| Argenx US, INC. | $42.65 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $40.09 | 2019-2024 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $38.32 | 2021 | |
| Sk Life Science, INC. | $36.35 | 2022 | |
| Eisai INC. | $33.51 | 2021-2024 | |
| Acadia Pharmaceuticals INC | $32.76 | 2021-2023 | Nuplazid |
| Mdd US Operations, LLC | $31.47 | 2019 | |
| Alexion Pharmaceuticals, INC. | $31.41 | 2020 | |
| Supernus Pharmaceuticals, INC. | $29.95 | 2019 | |
| Amneal Pharmaceuticals LLC | $29.70 | 2019-2023 | Rytary |
| Azurity Pharmaceuticals, INC. | $24.29 | 2022 | |
| Neurocrine Biosciences, INC. | $23.29 | 2023 | Ongentys, Ingrezza |
| Allergan, INC. | $17.67 | 2020 | |
| Strongbridge US INC. | $15.10 | 2019 | |
| Acorda Therapeutics, INC | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Burnbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.